Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207205 · ClinicalTrials.gov registry record · NA
Variability in the Measurement of WBCT Between Blood Drawn From Indwelling Catheters and Direct Venipuncture
A NA study, sponsored by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT02207205: Completed NA study, sponsored by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals.
NCT02207205 is a NA study that has completed, run by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02207205, a NA study, has completed, sponsored by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
1. Determine if there is any difference between the whole blood clotting time results obtained from blood drawn from indwelling catheters and direct venipuncture 2. Determine the intra-subject variability in both procedures
Interventions
- DRUG Blood drawn from indwelling catheters versus direct venipuncture
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-04 |
| Est. Completion | 2014-06 |
| Phase | NA |
Sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals9 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02207205
The ClinicalTrials.gov registry entry for NCT02207205 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood drawn from indwelling catheters versus direct venipuncture is the first listed.
NCT02207205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02207205 about?
NCT02207205 is a clinical study titled "Variability in the Measurement of WBCT Between Blood Drawn From Indwelling Catheters and Direct Venipuncture". 1. Determine if there is any difference between the whole blood clotting time results obtained from blood drawn from indwelling catheters and direct venipuncture 2. Determine the intra-subject variability in both procedures
What is the current status of trial NCT02207205?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2014-04. Estimated completion is 2014-06.
What interventions are being tested in trial NCT02207205?
The interventions under investigation include: Blood drawn from indwelling catheters versus direct venipuncture (DRUG).
Who is sponsoring clinical trial NCT02207205?
This trial is sponsored by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.